Kilifi Epilepsy Education Program (KEEP): An intervention to reduce the epilepsy treatment gap
Completed
- Conditions
- EpilepsyNervous System Diseases
- Registration Number
- ISRCTN35680481
- Lead Sponsor
- niversity College London (UCL) (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 740
Inclusion Criteria
1. PWE and their caregivers
2. Both male and female, no age limits
3. Where the person with epilepsy is a child, only caregiver will participate
Exclusion Criteria
1. PWE who refuse informed consent
2. Children whose parents refuse informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adherence of PWE to antiepileptic drugs (AEDs) as measured by drug levels. Plasma phenobarbital or phenytoin concentrations will be measured using an Abbott TDx FLx fluorescence polarisation immunoassay analyser (Abbott Laboratories, Diagnostic Division, Abbott Park, IL, USA). Therapeutic levels of AEDs will be defined as plasma concentrations ranging between 10 - 40 µg/mL, for both phenobarbital and phenytoin. Detectable levels of AEDs will be defined as plasma concentrations of greater than or equal to 1 µg/ml for both phenobarbital and phenytoin. Assessed at one year and four years after study onset.
- Secondary Outcome Measures
Name Time Method Assessed at one year and four years after study onset:<br>1. Seizure frequency, measured by a questionnaire<br>2. Quality of life of PWE, measured by quality of life questionnaire using Likert scale (0 = not at all, 1 = rarely, 2 = sometimes, 3 = most of the time, 4 = always)<br>3. Knowledge, beliefs and attitudes about epilepsy, measured by the Epilepsy beliefs and attitude questionnaire using Likert Scale (0 = don?t know, 1 = not at all, 2 = believe a little, 3 = totally believe)